HSA
Hussman Strategic Advisors Portfolio holdings
AUM
$438M
This Quarter Return
-3.49%
1 Year Return
+4.51%
3 Year Return
+35.81%
5 Year Return
+93.33%
10 Year Return
+242.61%
AUM
$524M
AUM Growth
+$524M
(-3.6%)
Cap. Flow
+$3.79M
Cap. Flow
% of AUM
0.72%
Top 10 Holdings %
Top 10 Hldgs %
11.58%
Holding
328
New
34
Increased
70
Reduced
63
Closed
32
Top Buys
| 1 |
AGCO
AGCO
|
$3.73M |
| 2 |
Fluence Energy
FLNC
|
$3.62M |
| 3 |
Marathon Petroleum
MPC
|
$3.18M |
| 4 |
Lamb Weston
LW
|
$2.91M |
| 5 |
Primoris Services
PRIM
|
$2.75M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$2.96M |
| 2 |
Williams-Sonoma
WSM
|
$2.6M |
| 3 |
United Parcel Service
UPS
|
$2.33M |
| 4 |
Ziff Davis
ZD
|
$2.17M |
| 5 |
United Therapeutics
UTHR
|
$2.05M |
Sector Composition
| 1 | Technology | 21.84% |
| 2 | Consumer Discretionary | 16.66% |
| 3 | Healthcare | 13.65% |
| 4 | Materials | 9.53% |
| 5 | Industrials | 8.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
226
Zynex
ZYXI
$45.1M
| $744K | 0.14% |
93,000
| – | – |
|
227
Kinross Gold
KGC
$26.6B
| $698K | 0.13% |
153,000
-75,600
| -33% | -$345K |
|
228
UGI
UGI
$7.3B
| $690K | 0.13% |
30,000
| – | – |
|
229
Vanda Pharmaceuticals
VNDA
$279M
| $674K | 0.13% |
156,000
| – | – |
|
230
Energizer
ENR
$1.94B
| $673K | 0.13% |
21,000
-10,000
| -32% | -$320K |
|
231
Palantir
PLTR
$367B
| $672K | 0.13% |
+42,000
| New | +$672K |
|
232
Ford
F
$46.2B
| $646K | 0.12% |
52,000
| – | – |
|
233
Align Technology
ALGN
$9.59B
| $641K | 0.12% |
+2,100
| New | +$641K |
|
234
Intrepid Potash
IPI
$392M
| $624K | 0.12% |
24,800
| – | – |
|
235
Schrodinger
SDGR
$1.42B
| $594K | 0.11% |
21,000
-10,000
| -32% | -$283K |
|
|
XYZ
236
Block, Inc.
XYZ
$46.2B
| $549K | 0.1% |
12,400
| – | – |
|
237
Associated Banc-Corp
ASB
$4.36B
| $530K | 0.1% |
31,000
| – | – |
|
238
Kulicke & Soffa
KLIC
$1.9B
| $511K | 0.1% |
10,500
-8,100
| -44% | -$394K |
|
239
Scansource
SCSC
$966M
| $509K | 0.1% |
16,800
-14,200
| -46% | -$430K |
|
240
Penumbra
PEN
$10.5B
| $508K | 0.1% |
+2,100
| New | +$508K |
|
241
Kimberly-Clark
KMB
$42.5B
| $508K | 0.1% |
4,200
-2,000
| -32% | -$242K |
|
242
Dynatrace
DT
$15.1B
| $491K | 0.09% |
+10,500
| New | +$491K |
|
243
MDU Resources
MDU
$3.3B
| $490K | 0.09% |
25,000
-10,000
| -29% | -$196K |
|
244
QuidelOrtho
QDEL
$1.87B
| $453K | 0.09% |
6,200
| – | – |
|
245
TG Therapeutics
TGTX
$5.03B
| $439K | 0.08% |
+52,500
| New | +$439K |
|
246
Pacific Biosciences
PACB
$378M
| $438K | 0.08% |
+52,500
| New | +$438K |
|
247
Merck
MRK
$210B
| $432K | 0.08% |
4,200
-2,000
| -32% | -$206K |
|
248
Exact Sciences
EXAS
$9.33B
| $430K | 0.08% |
+6,300
| New | +$430K |
|
249
Knife River
KNF
$4.34B
| $427K | 0.08% |
8,750
| – | – |
|
250
CRISPR Therapeutics
CRSP
$4.82B
| $422K | 0.08% |
9,300
| – | – |
|